Neurolytic celiac plexus block is a recognised treatment for visceral abdominal pain due to malignancy. The need for a diagnostic celiac plexus block prior to neurolytic blockade is of questionable value, as it may not predict a positive response and may incorrectly predict a lack of response. Our objective is to evaluate the efficacy of diagnostic celiac plexus block. The records of 59 patients treated with celiac plexus block during 1994-2000 were retrospectively reviewed. Diagnostic block was performed on 32 patients prior to the decision for subsequent neurolytic block (Group 1). Another 27 patients were directly treated with a neurolytic celiac plexus block (Group 2). Response of Group 1 to diagnostic and neurolytic blocks was compared. Data from Group 2 was used to project the response of Group 1 should those patients with negative response to diagnostic block proceeded to neurolytic block. A two-by-two table was then constructed. The diagnostic celiac plexus block predicted a positive response with a sensitivity of 93% and a specificity of 37%. The positive predictive value was 85% and the negative predictive value was 58%. The estimated "number needed to test" before a "true" nonrespondent to lytic block to be detected was 16.7. Therefore, a positive response to diagnostic block correlates positively with neurolytic celiac plexus block for abdominal visceral pain due to malignancy. However, diagnostic block is a poor predictor when the response is negative. Hence, its clinical role is questionable and may not be warranted for patients with terminal malignancy.
In managing patients with chronic pain, diagnostic neural blockade is a popular tool. Neural blockade targets the nociceptive component of pain, and abolishes sensory function of the intended nerves. However, the clinical presentation and the pathophysiology of chronic pain conditions are often inexactly defined, especially when various social, emotional, financial, and legal factors further compound the complexity. Therefore diagnostic neural blockade can be used to determine the nociceptive component of pain. Moreover, it also functions to anticipate the response to neuroablative therapies and guide clinicians towards formulating a plan of treatment.
Although it is commonly accepted and practised, nevertheless the efficacy of diagnostic blockade has not been substantiated by clinical studies in many chronic pain conditions. The practice of a diagnostic blockade with a poor efficacy may not predict a positive response and may incorrectly predict a lack of response. Hence, it may jeopardize patients' opportunity to proceed with the definitive neuroablative blockade.
This study reviewed the results of 59 patients who had celiac plexus block (CPB) for the management of upper abdominal visceral pain due to malignancy. We compared patients who had diagnostic CPD performed prior to neurolytic block with those who did not. In this study, we aim to draw conclusions regarding the value of diagnostic CPB and evaluate its clinical implication.
MATERIALS AND METHODS
This is a retrospective review. Patients included were all referred to the care of the Division of Pain Medicine, Department of Anaesthesiology, Queen Mary Hospital. Patients' data from 01/07/1994 to 31/12/2000 were retrieved from a computer database and clinical notes. All patients suffering from abdominal malignancy, including primary and secondary, who had celiac plexus block performed, were included. All data were updated until the last day of the study period.
The diagnoses recorded refer to the known primary site of malignancy. If the primary site was not known, the secondary site causing the abdominal symptoms was identified. The interval between pain occurrence and treatment was taken the from the patient's first complaint of pain requiring opioid analgesics on a regular basis until the first CPB was performed.
After initial assessment, the plan of analgesic management was formulated and explained to the patient. Analgesics were prescribed following the principle of WHO (World Health Organization) Analgesic Ladder 1 . When oral medications were not tolerated, transdermal, sublingual, parenteral injections and/or suppository route were considered. The rationale for CPB was introduced to all referred patients at their initial visit, including potential merits and complications. Indications for CPB included significant pain (verbal rating scale >3), intolerable analgesic sideeffects and requirement of potent opioids (WHO step III) 1 .
The verbal rating scale (VRS) was introduced to patients during the initial assessment (11 points scale from 0 to 10; when 0=no pain, 10=worst pain one can imagine) 2 . The scores before the CPB were taken on the day of the procedure. If patients were unable to comprehend the concept of VRS, a descriptive scale was used. We interpreted "severe" as VRS >6, 'moderate' as VRS 4-6 and "mild" as VRS 0-3. The post-CPB VRS for diagnostic block was recorded retrospectively the next day during the assessment. For neurolytic CPB, since the definitive effect takes some days to be evident, the recording was made between three and five days after the procedure. This interval also eliminated any residual effect due to the diagnostic block.
There were two groups of patients in our series. Group 1 had diagnostic block done prior to decision to proceed with neurolytic block. For Group 2, neurolytic block was done without a prior diagnostic block. Essentially, Group 1 patients were those referred to us in the first half of the series. We changed our policy and omitted the diagnostic block after mid-1999 because of controversies as presented in the discussion section. Patients presented to us since then comprised the Group 2 patients.
All CPBs were performed using a standard procedure and technique. No premedication was given. Sedation with intravenous midazolam aliquots (1 mg bolus) was titrated at the discretion of the operator. Patients were positioned in the prone position. We adopted the classic retrocrural technique as described by Moore 3 . Local infiltration with 2% lignocaine was used during introduction of the needles. Two 20 gauge 15 cm Quincke tip spinal needles (Becton Dickinson, Franklin Lakes, NJ, U.S.A.) were then positioned under fluoroscopic guidance, one at a time, aiming at the anterolateral aspect of the L1 vertebral body on both sides. The positioning of needles was verified by the spread of contrast (Iopamiro 300, Bracco s.p.a. Milano, Italy). Only if the contrast is confined within the lateral margins of the L1 body in anteroposterior projection, and in lateral view confined by the contour of the psoas fascia, will local anaesthetic be injected. For Group 1, diagnostic block was performed by injecting 20 ml 0.25% plain bupivacaine at each side (total 40 ml).
The decision to proceed to neurolytic block was made jointly by the patients and the attending pain specialists. The decision was primarily based on the analgesic response to the diagnostic block, sideeffects/complications experienced and the evolving clinical picture as a whole. All the neurolytic blocks were arranged for the earliest operating theatre session available once all the parties had agreed and at least 24 hours after the diagnostic block.
Neurolytic CPB was conducted in a similar fashion for all Group 2 patients and those Group 1 patients elected for the lytic block. Instead of using local anaesthetic alone, a 30 or 40 ml mixture of equal volumes of 0.5% plain bupivacaine and absolute ethanol (final concentration=0.25% plain bupivacaine and 50% ethanol) was injected, depending on the body weight of patients. The smaller dose of 30 ml was chosen for small adult or cachectic patients below 40 kg.
We had adopted either a decrease of 50% of a VRS score (for example: VRS from 8 to 4), a VRS <3 or an upgrading in descriptive scale (for example: severe to moderate, or moderate to mild) as positive response to diagnostic block. The same criteria were defined as the benchmark of success after lytic block.
RESULTS
During the study period, 32 diagnostic blocks and 55 neurolytic blocks were performed in 59 patients. Demographic data are presented in Table 1 . The mean interval between pain occurrence and CPB were 1.9 months (standard deviation, SD=1.08) for Group 1 and 1.6 months (SD=0.93) for Group 2 respectively. No statistical significance was noted.
Our patients represented a diversified group suf-fering from various primary and secondary tumours ( Figure 1 ). Except for carcinoma of the pancreas, however, the other groups showed different degree of heterogeneity in frequency distribution. In Group 1, 32 patients had diagnostic blocks, of whom 28 had a positive response. Only 27 proceeded with neurolytic block (Figure 2 ). On average, the interval between the two procedures was 4.6 days (range=1 to 18 days, SD=0.85). Reasons for not proceeding included negative response to diagnostic block (three patients, of which one had persistent intolerable nausea and vomiting, another two had persistent pain), rapidly deteriorating clinical condition (one patient) and evolving contraindication for invasive procedure (fever, septic) (one patient). All other patients achieved either a decrease of 50% of VRS score or VRS <3 with the diagnostic block and proceeded to lytic block. Lytic block was performed on one of the four negative respondents to the diagnostic block. This patient requested to proceed to lytic block although the diagnostic block did not satisfy the criteria for success. The result was, however, not satisfactory. For Group 2, one patient had neurolytic block performed twice for an unsatis--factory result after the first attempt. Table 2 shows the response of Group 1 patients who underwent neurolytic CPB. The positive predictive value of diagnostic block for subsequent neurolytic CPB is 85% (22/26, 95% CI=67%, 94%). Since the number of patients who did not respond to the diagnostic block but would have responded to the lytic block is not known from Group 1 (i.e. the value of "C" and "D" in Table 2 ), further statistical analysis regarding the sensitivity, specificity and negative predictive value cannot be determined.
To resolve the problem, we made use of data from Group 2 to project the number of patients who would have responded to lytic CPB irrespective of the results of the diagnostic block.
From Group 2 we know the overall success rate of lytic CPB was 79% (22/28, 95% CI=61%, 90%) and the failure rate was 21% (6/28) ( Therefore, the estimated positive predictive value is 85% (22/26), negative predictive value=58% (2.3/4); sensitivity=93% (22/23.7) and specificity= 37% (2.3/6.3)( Table 4 ).
We can also estimate the number of diagnostic blocks we need to perform before we can detect a "true" nonrespondent and therefore save the patient an otherwise useless lytic CPB. This can be calculated by the NNT ("number needed to test"). We applied the same principle of calculating the "number needed to treat" 4 in evaluating the efficacy of analgesics. In essence, NNT is calculated as the reciprocal of the reduction in risk of a failed lytic block when the diagnostic block is used. Since risk of a failed lytic block with diagnostic block is 4/26 ( Table 3 , Group 1) and that without a diagnostic block is 6/28 ( Table 3, In both groups, no major procedure-related complication was noted. All side-effects/complications recorded pertained to the group with neurolytic block done. Four patients developed diarrhoea, which subsided spontaneously after few days, and two patients developed de novo vomiting. Another three patients developed hypotension lasting more than one day. One of these three was, at least partly, attributed to coincidental massive upper gastrointestinal bleeding. One patient had severe bronchospasm immediately after the procedure. Whether the attack was due to an anaphylactoid reaction related to the agents used (i.e. radiocontrast, alcohol or bupivacaine) or provoked by sputum retention during the prone position/ sedation was not known. Three patients had persistent back pain for more than three days after the procedure which recovered with conservative treatment.
DISCUSSION
Neurolytic celiac plexus block is an established, well developed technique for treatment of pain due to visceral abdominal malignancy [5] [6] [7] . Its role in multidisciplinary pain management and palliative therapy is well accepted 8 . The mode of action, variety of techniques/approaches and complications has been extensively reviewed 9 . In our unit, the procedure was first performed in 1991.
Since the procedure is performed in a diversified group of patients with a variety of pathologies, stages of illness and perception/psychological element of pain, it is hard to predict the responsiveness of individual patients. Reasons for failure are multiple. Besides technical or procedural imperfection, it can also be attributed to a concomitant somatic component (e.g. significant peritoneal involvement) and extensive local metastases beyond the targeted plexus' innervation and the resultant inflammation 8 . Traditional teaching has recommended the use of diagnostic block with local anaesthetic to estimate the analgesic efficacy and to detect undesirable spread of agent to somatic nerve 4 , especially if radiographic guidance is not utilized. Others have considered pain relief from local anaesthetic a prerequisite before neuroablative techniques are pursued 10 . This also allows patients to experience the side-effects and imitates the sequelae of removing visceral afferent activity after the lytic CPB. More importantly, complications and side-effects due to the use of neurolytic agent can be avoided should patients decided not to proceed. Therefore, the role of diagnostic CPB before the lytic CPB would seem to be substantiated.
The practice of CPB varies considerably amongst different centres and there is no universal consensus. For instance, the institution of neurolytic block ranges from as soon as half an hour 11, 12 to within 24 hours 13 following the diagnostic block. In our series, diagnostic block was done at least one day before the lytic block. This allowed both the patients and the pain specialists ample time to decide whether to proceed. In our series, five patients declined the offer or were denied the offer of neurolytic block for various reasons. These included unpleasant experience persisting during or after the procedure (e.g. persistent nausea, vomiting), rapidly deteriorating clinical condition (e.g. sepsis) and unsatisfactory response to the diagnostic block. This is in contrast to some articles where no mention of negative response to diagnostic block is found [11] [12] [13] . We attributed the difference to the residual effect of local anaesthetic making diagnostic CPB highly efficacious or to a placebo effect too early to be disregarded by patients. In the study, we omitted analgesic consumption as an indicator when determining the success criteria of neural blockade. We consider analgesic consumption to be unreliable and nonspecific as a response indicator to CPB, as disease progression is a dynamic process and unmasking of pain could occur rendering other multidisciplinary treatment including the stepping-up of analgesic dose necessary. As research in neurobiology has progressed, preliminary mechanisms of how the element of affect 14 , patients' expectation 15 and attention 16 could affect the perception of pain are now better understood. These elements will inevitably influence our assessment of response to neural blockade. Thus, objective measurement is virtually impossible. The above discussion also explains the necessity for multiple criteria of success adopted in our study.
In our institution, diagnostic CPB was instituted for cancer pain patients in 1991 but has not been used since mid-1999. We have changed our policy because of reservations regarding the following issues. Basically, the efficacy and value of the diagnostic block are questionable 17 . As pointed out by Ischia et al 12 , a false positive can be due to 1) a placebo effect, 2) differences in local diffusion and mechanisms of action of the anaesthetic and of the neurolytic agent, and 3) systemic absorption of local anaesthetic. In the latter part of the series, diagnostic block was omitted for additional reasons: 4) the spread of neurolytic solution may not follow exactly that of local anaesthetic during the two procedures, 5) the patient being exposed to the doubled procedure-related risk, 6) evolving contraindication/clinical picture may preclude the patient from the lytic block (for example coagulopathy), 7) possible false negative diagnostic block due to various technical reasons, 8) a false negative side-effect profile due to local anaesthetic not equating that of the lytic agent and 9) doubling the health care cost.
A degree of non-homogeneity regarding the disease distribution was observed in Figure 1 . Nevertheless, we could find no reported evidence of a difference in response rate regarding gastrointestinal tumours at various sites. The exception is carcinoma of the pancreas 13 . In fact, according to the metaanalysis by Eisenberg of 1145 patients 6 , patients with pancreatic cancer respond similarly to those with other intra-abdominal malignancies. Brown 7 also reported a comparable response rate with nonpancreatic intra-abdominal pain. We therefore believe that the heterogeneity should not impact greatly on our interpretation and conclusion.
The question is, therefore, what are the benefits of omitting diagnostic CPB? As shown in our series, the negative predictive value is 58%. This implies that 42% of those negative respondents in Group 1 could have had apositive response from neurolytic CPB. Thus, by omitting the diagnostic CPB, these patients will not be jeopardized from effective neurolytic CPB for pain control. The poor value of diagnostic block is also represented by the NNT value of 16.7. It means that on average we need to perform around 16-17 diagnostic blocks to prevent one useless lytic CPB. The two-stage procedure has also financial implication, doubling the session time may not be justified as cost-effective in view of the above. Furthermore, the two patients denied neurolytic block because of then rapidly deteriorating clinical condition with evolving sepsis contraindicating invasive procedures.
Diagnostic CPB is unable to predict the side-effects and complications after the lytic block. In our series, the incidence appeared low and was at least partly attributable to the underlying disease. Common adverse effects were transient and included local pain, diarrhoea and hypotension and the overall rate as was reported by Eisenberg 6 2%. Two patients in our series developed severe vomiting after the lytic CPB. The mechanism and treatment of this has been discussed by Iftikhar 18 .
Technology has evolved since the description of the procedure. Although not shown to produce higher success rates or lower adverse incidence rates 6 , many centres now resort to more sophisticated imaging modalities like computer aided tomography or ultrasonography to aid the proper positioning of the needle before injection of lytic material 19, 20 . Hence precise localization is more likely in the future.
In summary, we examined the significance of diagnostic CPB in the prediction of responsiveness to neurolytic CPB by retrospectively analyzing two groups of patients suffering from pain due to abdominal malignancy. The result suggests diagnostic CPB has a high positive predictive value (85%) and sensitivity (93%) but an equivocal negative predictive value (58%) and specificity (37%). In other words, negative response is a poor predictor of the eventual outcome after a lytic block.
Therefore, in conclusion, the clinical significance of diagnostic CPB is questionable and its routine use is not warranted before implementation of neurolytic CPB for pain due to visceral abdominal malignancy. Clinicians should exercise their own judgment regarding the value of a procedure; discuss the pros and cons in the best interest of patients before proceeding.
